Clinical Usefulness of Serum Prostate Specific Antigen for the Detection of Prostate Cancer is Preserved in Men Receiving the Dual 5α-Reductase Inhibitor Dutasteride

Journal of Urology

Volumn 175, Issue 5, 2006, Pages 1657-1662

  Andriole, Gerald L ^a   Marberger, Michael ^b   Roehrborn, Claus G ^c  

^a WASHINGTON UNIVERSITY   (United States)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

dutasteride; prostate; prostate specific antigen; prostatic hyperplasia; prostatic neoplasms

Indexed keywords

DUTASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; ARTICLE; CALCULATION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SCREENING; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DOUBLE BLIND PROCEDURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; AZASTEROIDS; CHOLESTENONE 5 ALPHA-REDUCTASE; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS;

EID: 33646006372     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)00984-5     Document Type: Article

References (18)

1. Cooner W.H., Mosley B.R., Rutherford Jr. C.L., Beard J.H., Pond H.S., Terry W.J., et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 143 (1990) 1146
2. Labrie F., Candas B., Dupont A., Cusan L., Gomez J.L., Suburu R.E., et al. Screening decreases prostate cancer death. first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 38 (1999) 83
3. Raaijmakers R., Wildhagen M.F., Ito K., Paez A., de Vries S.H., Roobol M.J., et al. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Urology 63 (2004) 316
4. Roobol M.J., Kranse R., de Koning H.J., and Schroder F.H. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer. results of second screening round of ERSPC (ROTTERDAM). Urology 63 (2004) 309
5. Span P.N., Voller M.C., Smals A.G.H., Sweep F.G.J., Schalken J.A., Feneley M.R., et al. Selectivity of finasteride as an in vivo inhibitor of 5 alpha-reductase isozyme enzymatic activity in the human prostate. J Urol 161 (1999) 332
6. Andriole G.L., Guess H.A., Epstein J.I., Wise H., Kadmon D., Crawford E.D., et al., PLESS Study Group. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer. results of a randomized, double-blind, placebo-controlled clinical trial. Proscar Long-Term Efficacy and Safety Study Urology 52 (1998) 195
7. Bramson H.N., Hermann D., Batchelor K.W., Lee F.W., James M.K., and Frye S.V. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther 282 (1997) 1496
8. Clark R.V., Hermann D.J., Batriel H., Wilson T.H., Merrill B.B., and Hobbs S. Effective suppression of dihydrotestosterone (DHT) by GI198745, a novel, dual 5 alpha reductase inhibitor. J Urol 161 suppl. (1999) 268 abstract 1037
9. Roehrborn C.G., Boyle P., Nickel J.C., Hoefner K., and Andriole G. ARIA3001, ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60 (2002) 434
10. Debruyne F., Barkin J., van Erps P., Reis M., Tammela T.L., Roehrborn C., et al. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 46 (2004) 488
11. Hanley J.A., and McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143 (1982) 29
12. Simel D.L., Samsa G.P., and Matchar D.B. Likelihood ratios with confidence. sample size estimates for diagnostic test studies. J Clin Epidemiol 44 (1991) 763
13. Zweig M.H., and Campbell G. receiver-operating characteristic (ROC) plots. a fundamental evaluation tool in clinical medicine. Clin Chem 39 (1993) 561
14. Magklara A., Scorilas A., Stephan C., Kristiansen G.O., Hauptmann S., Jung K., et al. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology 56 (2000) 527
15. Bartsch G., Fitzpatrick J.M., Schalken J.A., Isaacs J., Nordling J., and Roehrborn C.G. Consensus statement. role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia. BJU Int 93 suppl. (2004) 27
16. Stamey T.A., Yang N., Hay A.R., McNeal J.E., Freiha F.S., and Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317 (1987) 909
17. Andriole G., Lieber M., Smith J., Soloway M., Schroeder F., Kadmon D., et al. Treatment with finasteride following radical prostatectomy for prostate cancer. Urology 45 (1995) 491
18. Thompson I.M., Pauler D.K., Goodman P.J., Tangen C.M., Lucia M.S., Parnes H.L., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350 (2004) 2239